Free Trial
NASDAQ:PEPG

PepGen Q1 2025 Earnings Report

PepGen logo
$1.32 -0.05 (-3.65%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.32 -0.01 (-0.38%)
As of 08/1/2025 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PepGen EPS Results

Actual EPS
-$0.92
Consensus EPS
-$0.72
Beat/Miss
Missed by -$0.20
One Year Ago EPS
N/A

PepGen Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PepGen Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

PepGen's Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

PepGen Earnings Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
See More PepGen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PepGen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PepGen and other key companies, straight to your email.

About PepGen

PepGen (NASDAQ:PEPG) Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

View PepGen Profile

More Earnings Resources from MarketBeat